DPTX3186 for Wnt-pathway activated solid tumors
Official title: An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist
Run by Dewpoint Therapeutics · NCT07312903 · Data updated 2026-11-12
This first-in-human study will try an oral drug called DPTX3186 in adults whose solid tumors are driven by the Wnt pathway and who have no approved treatment options left.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Dewpoint Therapeutics Industry-sponsored |
| Locations | 8 sites (Los Angeles, California and 7 other locations) |
| Status | Recruiting |
| Started | January 29, 2026 |
| Main results expected | May 31, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT07312903 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with histologically or cytologically confirmed solid tumors known to be Wnt-pathway activated (for example colorectal, gastric, certain lung cancers, or triple-negative breast cancer), at least one measurable lesion, ECOG 0–1, life expectancy ≥3 months, and no approved treatment options available are the intended candidates.
✕Probably not a fit
Patients with symptomatic or uncontrolled brain metastases requiring treatment, another progressing malignancy needing therapy, inadequate organ function, known hypersensitivity to the drug, or conditions that prevent reliable oral drug absorption are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, first-in-human trial of DPTX3186 given to adults with solid tumors known to have Wnt-pathway activation. The study will escalate doses to define safety and pharmacokinetics, record any early signs of anti-tumor activity, and collect samples to explore pharmacodynamic biomarkers. Eligible patients must have measurable disease, good performance status (ECOG 0–1), and limited remaining standard treatment options. The drug is administered orally and participants will be seen at specialized clinical research sites for dosing and monitoring.
Why it matters
Potential benefit: If successful, DPTX3186 could provide a new targeted oral treatment option for patients with Wnt-activated cancers who currently lack approved therapies.
How similar studies have gone: Wnt-pathway targeting is an active but challenging area with few proven therapies so far, making this approach relatively novel with limited prior clinical success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available. * At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI. * ECOG performance status of 0 or 1. * Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy. * Age ≥18 years (or ≥ age of majority per local regulation) * Life expectancy ≥3 months * Willing and able to comply with protocol requirements Exclusion Criteria: * Symptomatic or uncontrolled brain metastasis requiring concurrent treatment, * Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.). * Inadequate organ function * Known hypersensitivity to study drug or excipients * Known history of human immunodeficiency virus (HIV) infection. * Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C (HCV) infection viral load.
Where it's running
-
UCLA
Los Angeles, California, United States Recruiting -
University Of Colorado
Boulder, Colorado, United States Recruiting -
Yale
New Haven, Connecticut, United States Recruiting -
Columbia University
New York, New York, United States Recruiting -
Dana Farber Cancer Institute
Boston, Tennessee, United States Recruiting -
MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Show 2 more locations
-
NEXT San Antonio
San Antonio, Texas, United States Recruiting -
NEXT Virginia
Fairfax, Virginia, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.